---
title: "Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294061154.md"
description: "A third program from the company has entered the clinical development phase using the FORCE platform. The objective is to achieve significant functional improvement in a rare neuromuscular disease. This initiative underscores the company's commitment to addressing rare diseases through innovative solutions."
datetime: "2026-07-28T11:34:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294061154.md)
  - [en](https://longbridge.com/en/news/294061154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294061154.md)
generator: "portal-rs"
---

# Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

A third program from the company has entered the clinical development phase using the FORCE platform. The objective is to achieve significant functional improvement in a rare neuromuscular disease. This initiative underscores the company's commitment to addressing rare diseases through innovative solutions.

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)

## Related News & Research

- [Dyne Therapeutics director Jason P. Rhodes disposes of common shares worth $67.45 million](https://longbridge.com/en/news/296148351.md)
- [Dyne Therapeutics grants new-hire equity awards for 212,500 shares under inducement plan](https://longbridge.com/en/news/296530830.md)
- [Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN](https://longbridge.com/en/news/296188072.md)
- [Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN](https://longbridge.com/en/news/296588788.md)
- [Myriad Uranium wins final court approval for Rush Rare Metals acquisition](https://longbridge.com/en/news/296538572.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**